Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth

BACKGROUND: Patients with advanced colorectal cancer (CRC) have a poor prognosis. Combinations of immunotherapies and anti-angiogenic agents are currently being evaluated in clinical trials. In this study, the multikinase inhibitor regorafenib (REG) was combined with an anti-programmed cell death pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Doleschel, Dennis, Hoff, Sabine, Koletnik, Susanne, Rix, Anne, Zopf, Dieter, Kiessling, Fabian, Lederle, Wiltrud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436536/
https://www.ncbi.nlm.nih.gov/pubmed/34517894
http://dx.doi.org/10.1186/s13046-021-02043-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436536/
https://www.ncbi.nlm.nih.gov/pubmed/34517894
http://dx.doi.org/10.1186/s13046-021-02043-0

Ejemplares similares